الفهرس 
Title : Study of the possible protective effect of NADPH oxidase inhibitor and escitalopram in d-galactose-treated
ContentsOnly 14 pages are availabe for public view
 |  | from | 129 |  |  |
| | | from | 129 | | |
Abstract
Though selective serotonin reuptake inhibitors (SSRIs) have been shown to increase cognitive performance in some studies on patients and animal models of Alzheimer’s disease (AD), other studies reported contradictory results and the mechanism of action hasn’t been fully described. Further, NADPH oxidase (NOX) has emerged as crucial contender of oxidative damage in AD, however, the ability of diapocynin, a NOX inhibitor, to offer neuroprotection in AD models is a matter of debate. Therefore, this study aimed at investigating the effect of escitalopram, an SSRI, or diapocynin on AD experimental model, in addition to elucidating neuronal survival and apoptotic pathways regulating their effects. Female rats were ovariectomized and received d-galactose (150 mg/kg/day, i.p) for 10 weeks for AD development. Starting from the 7th week, they were treated with escitalopram or diapocynin (10 mg/kg/day, p.o) for 4 weeks. Treatment with escitalopram or diapocynin improved cognitive functions as confirmed using Morris water maze and novel object recognition tests along with histopathological imaging. Moreover, both treatments reduced the hippocampal amyloid Ý 42, Ý-secretase, and p-tau, while increasing Ü- secretase